Adolescence has become one of the most stubborn fault lines in the global HIV response. Antiretroviral therapy (ART) has transformed HIV from a fatal infection into a manageable chronic condition for many people, and AIDS-related deaths have dropped sharply in most age groups. Yet research and program reports continue to show that adolescents living with HIV die at higher rates than their peers in the general population—and, in many settings, fare worse than both children and adults living with the virus.
One driver is simple access. Across countries, adolescents are less likely than adults to be on treatment: about six in ten adolescents living with HIV receive ART, compared with roughly four in five people living with HIV overall, according to global estimates. But access is only part of the story. Adolescence is also a period when lifelong daily medication routines collide with stigma, school schedules, mental health challenges, and shifting family support. Studies repeatedly link these pressures to missed doses and treatment interruptions, which can lead to unsuppressed viral load—raising the risks of opportunistic infections, drug resistance, clinical failure and, ultimately, death.
A large multi-regional analysis of routine clinical data underscores how mortality risks in youth are not uniform—and how the pathway into HIV care matters. Drawing on programmatic records from the International epidemiology Databases to Evaluate AIDS (IeDEA) collaboration, researchers tracked more than 100,000 adolescents and young adults aged 10–24 years who had started ART and were followed in care between 2004 and 2016 across six world regions (including multiple sub-Saharan African regions, Asia-Pacific, and the Americas).
Because many clinics do not reliably record the mode of HIV acquisition, investigators used age at enrollment into care as a proxy to distinguish two broad groups: those likely living with perinatally acquired HIV (enrolled in care before age 10) and those more likely to have acquired HIV later (enrolled at 10–24 years). The analysis then compared post-ART mortality rates, adjusting for factors including sex, geographic region, age band, CD4 count at ART initiation, and time on treatment.
The findings reveal a striking contrast. Overall mortality after starting ART was substantially higher among youth who entered care later—those classified as non-perinatal—than among those enrolled before age 10. Mortality incidence was estimated at about 2.3 deaths per 100 person-years in the later-enrolling group, versus about 0.7 per 100 person-years in the early-enrolling group. Among 10–19-year-olds, the pattern persisted across regions and sexes, with mortality consistently lower in the early-enrolled cohort; reported incidence rate ratios in sub-analyses were well below 1, indicating a protective association of earlier engagement in care relative to later entry.
At first glance, this may seem counterintuitive. Perinatally infected adolescents often face long treatment histories, potential drug resistance, and complex clinical needs. But experts say the results align with what clinicians observe: adolescents who acquired HIV later frequently reach services only after months or years of infection, often with advanced disease, low CD4 counts, or concurrent social vulnerabilities. Late diagnosis can also mean a late start to adherence support—especially for youth navigating first relationships, disclosure fears, or gender-based power imbalances.
The regional data also carry a warning: a “substantial amount” of deaths occurred during adolescence itself, not only as youth transition into adult care. That matters because health systems often treat adolescence as a brief handoff period—moving patients from pediatric to adult clinics—rather than a high-risk developmental window requiring tailored support.
Researchers and implementers point to several interventions that could narrow the mortality gap. First is expanding youth-friendly HIV testing and rapid linkage to care—particularly for those who acquire HIV in adolescence and may not see themselves at risk. Second is strengthening adherence and mental health support in ways that fit adolescent lives: flexible clinic hours, peer navigators, simplified drug regimens, and nonjudgmental counseling around disclosure and sexuality. Longer-acting ART formulations, where available and appropriate, are also being studied as a strategy to reduce the burden of daily pills, though questions remain about implementation, cost, and sustained follow-up.
Finally, better data are essential. Global modeling tools used for national targets rely on accurate age-specific mortality estimates. Yet estimates for older adolescents and young adults are often less precise than for children. Large routine-care datasets, like those analyzed across IeDEA regions, help fill this gap and can improve planning for the growing population of youth living with HIV—both those aging up from pediatric infection and those newly infected in adolescence.
Why it matters
Adolescents are one of the few groups not seeing the same pace of HIV mortality decline as others, despite effective treatment. The evidence suggests that late diagnosis and delayed engagement in care—common among teens who acquire HIV during adolescence—are major, preventable contributors. Closing the mortality gap will require youth-specific testing, rapid linkage, and adherence support designed for the realities of adolescent life.